<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02668341</url>
  </required_header>
  <id_info>
    <org_study_id>IVDP-405-14</org_study_id>
    <nct_id>NCT02668341</nct_id>
  </id_info>
  <brief_title>Cross Sectional Analysis of Healthcare for Psoriasis in 5 European Countries</brief_title>
  <acronym>PsoBarrier</acronym>
  <official_title>PsoBarrierEU - Barrier Analysis of Guideline-Compliant Healthcare for Psoriasis in Europe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Analysis of barriers in psoriasis care from the patient's and the physician's perspective and
      generation of scientific data on the quality of health care in Denmark, Poland, Spain, United
      Kingdom, and Germany
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cross-sectional, non-interventional study on healthcare for psoriasis in patients and their
      treating physicians. Clinical data on severity as well as subjective estimates on disease
      burden, quality of life etc. will be collected. Data collection is planned at multiple,
      representative sites in five European countries with different healthcare systems with the
      aim to identify system-dependent and -independent barriers in guideline-compliant psoriasis
      care.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with severe disease receiving systemic treatment</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Area and Severity Index (PASI)</measure>
    <time_frame>Baseline</time_frame>
    <description>Psoriasis disease severity, measured by validated instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Surface Area (BSA)</measure>
    <time_frame>Baseline</time_frame>
    <description>Psoriasis-affected body area, measured by physician estimate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Baseline</time_frame>
    <description>Quality of life assessment in dermatologic patients, measured by validated quality of life instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQuol (EQ-5D)</measure>
    <time_frame>Baseline</time_frame>
    <description>generic quality of life assessment, measured by validated visual analogue scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with comorbidities receiving treatment.</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>psoriasis patients in Denmark</arm_group_label>
    <description>non-interventional survey study in psoriasis patients in daily practice care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>psoriasis patients in United Kingdom</arm_group_label>
    <description>non-interventional survey study in psoriasis patients in daily practice care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>psoriasis patients in Spain</arm_group_label>
    <description>non-interventional survey study in psoriasis patients in daily practice care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>psoriasis patients in Poland</arm_group_label>
    <description>non-interventional survey study in psoriasis patients in daily practice care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>psoriasis patients in Germany</arm_group_label>
    <description>non-interventional survey study in psoriasis patients in daily practice care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>non-interventional</intervention_name>
    <description>non-interventional survey study</description>
    <arm_group_label>psoriasis patients in Denmark</arm_group_label>
    <arm_group_label>psoriasis patients in United Kingdom</arm_group_label>
    <arm_group_label>psoriasis patients in Spain</arm_group_label>
    <arm_group_label>psoriasis patients in Poland</arm_group_label>
    <arm_group_label>psoriasis patients in Germany</arm_group_label>
    <other_name>non-interventional survey study</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        adult patients with diagnosed psoriasis vulgaris
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinically diagnosed psoriasis vulgaris

          -  age ≥ 18

          -  written informed consent

        Exclusion Criteria:

          -  lack of mental, physical or linguistic ability to participate in a questionnaire
             survey
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Augustin, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide group of dermatological centers, hospitals and medical offices</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Poznan</name>
      <address>
        <city>Poznan</city>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Manchester</name>
      <address>
        <city>Manchester</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2015</study_first_submitted>
  <study_first_submitted_qc>January 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2016</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

